Horizant Tablet, Extended Release
Product Images NDC 53451-0103

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Horizant (NDC 53451-0103). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Azurity Pharmaceuticals, Inc. (formerly Arbor Pharmaceuticals), these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Horizant 01)

FDA Label Image

Figure 1 (Horizant 02)

Figure 1 (Horizant 02)
The text represents data on the response rate of placebo and two doses (600mg and 1200mg) of HORIZANT medication collected over a course of 12 weeks in a clinical study. The data is presented in a table with different time points and observed cases. The response rate for each group is shown as a percentage.*
FDA Label Image

Figure 2 (Horizant 03)

Figure 2 (Horizant 03)
This is a chart displaying the percentage of patients who improved after taking different doses of HORIZANT and Placebo. The chart also shows the percentage improvement in pain from baseline. No further information is available.*
FDA Label Image

Principal Display Panel (300 mg Bottle Label)

Principal Display Panel (300 mg Bottle Label)
This is a medication information label for Horizant, an extended-release tablet containing 300mg of gabapentin enacarbil. The tablets should not be cut, crushed, or chewed and are not interchangeable with other gabapentin products. The prescribing information should be consulted for dosage information, and the tablets should be stored at room temperature and protected from moisture. The medication guide should be dispensed to each patient. The label also includes the manufacturer's address, a lot number, and an expiration date.*
FDA Label Image

Principal Display Panel (600 mg Bottle Label)

Principal Display Panel (600 mg Bottle Label)
This is a medication information for Horzant, an extended-release tablet containing 600mg of gabapentin enacarbil, which is not interchangeable with other gabapentin products. The tablets should be swallowed whole, and not cut, crushed, or chewed. The prescribing information contains dosage instructions. The tablets should be stored at 25°C, with excursions permitted between 15-30°C. The medication should be protected from moisture, and the safety seal under the cap should not be broken or missing. The accompanying medication guide should be dispensed to each patient. Horzant is a registered trademark of Arbor Pharmaceuticals. Only available by prescription.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.